Why Did Americans Pay Billions for a Drug Deemed Worthless in Other Countries

The following excerpt is from an article that originally appeared on Natural Blaze

By Natural Blaze

“Disease awareness campaigns…are an effective way for companies to sell a disease to sell a drug.“ Why did Americans pay more than $1.5 billion a year in 2016 alone for a drug that potentially does so little, and to treat a condition that many would not even consider to be a disease?

Why are Americans – both as patients and taxpayers – paying billions of dollars for a drug whose efficacy is so questionable that it’s not approved in the European Union, Australia or New Zealand?

Restasis is a blockbuster drug sold by Allergan to treat chronic dry eye. It has done $8.8 billion in U.S. sales between 2009 and 2015, including over $2.9 billion in public monies through Medicare Part D, according to a Dartmouth Institute.

Restasis and Allergan have been in the news lately due to the company’s novel legal strategy of transferring their

Click here to Read this Entire Story on Natural Blaze


This post was originally published on this site
Comments are closed.